Fortress Biotech, Inc. (NASDAQ: FBIO) Stock Competitors & Peer Comparison
See FBIO's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for FBIO and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| FBIO | $2.03 | -2.17% | 67.4M | 0.77 | $2.64 | N/A |
| VRTX | $504.60 | -0.42% | 128.1B | 26.52 | $19.03 | N/A |
| REGN | $735.20 | +0.05% | 75.7B | 16.11 | $45.63 | +0.50% |
| MRNA | $190.01 | +0.57% | 75.4B | -23.31 | -$8.15 | N/A |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $919.28 | -1.79% | 57.2B | 33.14 | $27.73 | N/A |
| RVMDW | $11.52 | -0.69% | 45.2B | -1.31 | -$8.82 | N/A |
| RVMD | $206.64 | +0.36% | 43.9B | -23.43 | -$8.82 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ONC | $358.07 | -0.20% | 38.3B | 63.04 | $5.68 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
FBIO vs VRTX Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, VRTX has a market cap of 128.1B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while VRTX trades at $504.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas VRTX's P/E ratio is 26.52. In terms of profitability, FBIO's ROE is +1.04%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, FBIO is more volatile compared to VRTX. This indicates higher risk in terms of short-term price fluctuations for FBIO.Check VRTX's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
FBIO vs REGN Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, REGN has a market cap of 75.7B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while REGN trades at $735.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas REGN's P/E ratio is 16.11. In terms of profitability, FBIO's ROE is +1.04%, compared to REGN's ROE of +0.14%. Regarding short-term risk, FBIO is more volatile compared to REGN. This indicates higher risk in terms of short-term price fluctuations for FBIO.Check REGN's competition here
Moderna, Inc. (NASDAQ: MRNA)
FBIO vs MRNA Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, MRNA has a market cap of 75.4B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while MRNA trades at $190.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas MRNA's P/E ratio is -23.31. In terms of profitability, FBIO's ROE is +1.04%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, FBIO is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for FBIO.Check MRNA's competition here
Verona Pharma plc (NASDAQ: VRNA)
FBIO vs VRNA Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas VRNA's P/E ratio is -102.80. In terms of profitability, FBIO's ROE is +1.04%, compared to VRNA's ROE of -0.61%. Regarding short-term risk, FBIO is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for FBIO.Check VRNA's competition here
argenx SE (NASDAQ: ARGX)
FBIO vs ARGX Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, ARGX has a market cap of 57.2B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while ARGX trades at $919.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas ARGX's P/E ratio is 33.14. In terms of profitability, FBIO's ROE is +1.04%, compared to ARGX's ROE of +0.24%. Regarding short-term risk, FBIO is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for FBIO.Check ARGX's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
FBIO vs RVMDW Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, RVMDW has a market cap of 45.2B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while RVMDW trades at $11.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas RVMDW's P/E ratio is -1.31. In terms of profitability, FBIO's ROE is +1.04%, compared to RVMDW's ROE of -0.96%. Regarding short-term risk, FBIO is more volatile compared to RVMDW. This indicates higher risk in terms of short-term price fluctuations for FBIO.Check RVMDW's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
FBIO vs RVMD Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, RVMD has a market cap of 43.9B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while RVMD trades at $206.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas RVMD's P/E ratio is -23.43. In terms of profitability, FBIO's ROE is +1.04%, compared to RVMD's ROE of -0.96%. Regarding short-term risk, FBIO is more volatile compared to RVMD. This indicates higher risk in terms of short-term price fluctuations for FBIO.Check RVMD's competition here
Seagen Inc. (NASDAQ: SGEN)
FBIO vs SGEN Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas SGEN's P/E ratio is -57.19. In terms of profitability, FBIO's ROE is +1.04%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, FBIO is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for FBIO.Check SGEN's competition here
BeOne Medicines AG (NASDAQ: ONC)
FBIO vs ONC Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, ONC has a market cap of 38.3B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while ONC trades at $358.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas ONC's P/E ratio is 63.04. In terms of profitability, FBIO's ROE is +1.04%, compared to ONC's ROE of +0.14%. Regarding short-term risk, FBIO is more volatile compared to ONC. This indicates higher risk in terms of short-term price fluctuations for FBIO.Check ONC's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
FBIO vs ALNY Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, ALNY has a market cap of 29.4B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while ALNY trades at $220.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas ALNY's P/E ratio is 39.59. In terms of profitability, FBIO's ROE is +1.04%, compared to ALNY's ROE of +0.94%. Regarding short-term risk, FBIO is less volatile compared to ALNY. This indicates lower risk in terms of short-term price fluctuations for FBIO.Check ALNY's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
FBIO vs ROIV Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, ROIV has a market cap of 25.8B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while ROIV trades at $35.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas ROIV's P/E ratio is -33.98. In terms of profitability, FBIO's ROE is +1.04%, compared to ROIV's ROE of -0.06%. Regarding short-term risk, FBIO is more volatile compared to ROIV. This indicates higher risk in terms of short-term price fluctuations for FBIO.Check ROIV's competition here
BioNTech SE (NASDAQ: BNTX)
FBIO vs BNTX Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, BNTX has a market cap of 24.3B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while BNTX trades at $96.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas BNTX's P/E ratio is -12.57. In terms of profitability, FBIO's ROE is +1.04%, compared to BNTX's ROE of -0.09%. Regarding short-term risk, FBIO is more volatile compared to BNTX. This indicates higher risk in terms of short-term price fluctuations for FBIO.Check BNTX's competition here
Insmed Incorporated (NASDAQ: INSM)
FBIO vs INSM Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, INSM has a market cap of 24.1B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while INSM trades at $111.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas INSM's P/E ratio is -27.04. In terms of profitability, FBIO's ROE is +1.04%, compared to INSM's ROE of -1.11%. Regarding short-term risk, FBIO is less volatile compared to INSM. This indicates lower risk in terms of short-term price fluctuations for FBIO.Check INSM's competition here
Incyte Corporation (NASDAQ: INCY)
FBIO vs INCY Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, INCY has a market cap of 23.4B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while INCY trades at $115.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas INCY's P/E ratio is 15.50. In terms of profitability, FBIO's ROE is +1.04%, compared to INCY's ROE of +0.30%. Regarding short-term risk, FBIO is more volatile compared to INCY. This indicates higher risk in terms of short-term price fluctuations for FBIO.Check INCY's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
FBIO vs UTHR Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, UTHR has a market cap of 23B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while UTHR trades at $541.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas UTHR's P/E ratio is 19.38. In terms of profitability, FBIO's ROE is +1.04%, compared to UTHR's ROE of +0.20%. Regarding short-term risk, FBIO is less volatile compared to UTHR. This indicates lower risk in terms of short-term price fluctuations for FBIO.Check UTHR's competition here
Genmab A/S (NASDAQ: GMAB)
FBIO vs GMAB Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, GMAB has a market cap of 21.3B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while GMAB trades at $34.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas GMAB's P/E ratio is 26.19. In terms of profitability, FBIO's ROE is +1.04%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, FBIO is more volatile compared to GMAB. This indicates higher risk in terms of short-term price fluctuations for FBIO.Check GMAB's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
FBIO vs BGNE Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas BGNE's P/E ratio is -22.55. In terms of profitability, FBIO's ROE is +1.04%, compared to BGNE's ROE of +0.14%. Regarding short-term risk, FBIO is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for FBIO.Check BGNE's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
FBIO vs DNA-WT Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, FBIO's ROE is +1.04%, compared to DNA-WT's ROE of -0.60%. Regarding short-term risk, FBIO is less volatile compared to DNA-WT. This indicates lower risk in terms of short-term price fluctuations for FBIO.Check DNA-WT's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
FBIO vs JAZZ Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, JAZZ has a market cap of 14.8B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while JAZZ trades at $235.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas JAZZ's P/E ratio is 8.79. In terms of profitability, FBIO's ROE is +1.04%, compared to JAZZ's ROE of +0.21%. Regarding short-term risk, FBIO is more volatile compared to JAZZ. This indicates higher risk in terms of short-term price fluctuations for FBIO.Check JAZZ's competition here
Exelixis, Inc. (NASDAQ: EXEL)
FBIO vs EXEL Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, EXEL has a market cap of 14.7B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while EXEL trades at $58.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas EXEL's P/E ratio is 16.68. In terms of profitability, FBIO's ROE is +1.04%, compared to EXEL's ROE of +0.42%. Regarding short-term risk, FBIO is more volatile compared to EXEL. This indicates higher risk in terms of short-term price fluctuations for FBIO.Check EXEL's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
FBIO vs NBIX Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, NBIX has a market cap of 14.4B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while NBIX trades at $143.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas NBIX's P/E ratio is 20.69. In terms of profitability, FBIO's ROE is +1.04%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, FBIO is more volatile compared to NBIX. This indicates higher risk in terms of short-term price fluctuations for FBIO.Check NBIX's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
FBIO vs ASND Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, ASND has a market cap of 14.2B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while ASND trades at $227.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas ASND's P/E ratio is -94.16. In terms of profitability, FBIO's ROE is +1.04%, compared to ASND's ROE of +1.90%. Regarding short-term risk, FBIO is more volatile compared to ASND. This indicates higher risk in terms of short-term price fluctuations for FBIO.Check ASND's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
FBIO vs SMMT Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, SMMT has a market cap of 13.4B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while SMMT trades at $16.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas SMMT's P/E ratio is -14.96. In terms of profitability, FBIO's ROE is +1.04%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, FBIO is similarly volatile compared to SMMT. This indicates similar risk in terms of short-term price fluctuations for FBIO.Check SMMT's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
FBIO vs BBIO Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, BBIO has a market cap of 13.2B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while BBIO trades at $67.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas BBIO's P/E ratio is -17.98. In terms of profitability, FBIO's ROE is +1.04%, compared to BBIO's ROE of +0.32%. Regarding short-term risk, FBIO is more volatile compared to BBIO. This indicates higher risk in terms of short-term price fluctuations for FBIO.Check BBIO's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
FBIO vs HALO Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, HALO has a market cap of 12.7B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while HALO trades at $109.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas HALO's P/E ratio is 19.95. In terms of profitability, FBIO's ROE is +1.04%, compared to HALO's ROE of +1.81%. Regarding short-term risk, FBIO is more volatile compared to HALO. This indicates higher risk in terms of short-term price fluctuations for FBIO.Check HALO's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
FBIO vs KRTX Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas KRTX's P/E ratio is -28.09. In terms of profitability, FBIO's ROE is +1.04%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, FBIO is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for FBIO.Check KRTX's competition here
10x Genomics, Inc. (NASDAQ: TXG)
FBIO vs TXG Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, TXG has a market cap of 11.9B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while TXG trades at $93.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas TXG's P/E ratio is -158.47. In terms of profitability, FBIO's ROE is +1.04%, compared to TXG's ROE of -0.09%. Regarding short-term risk, FBIO is less volatile compared to TXG. This indicates lower risk in terms of short-term price fluctuations for FBIO.Check TXG's competition here
Twist Bioscience Corporation (NASDAQ: TWST)
FBIO vs TWST Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, TWST has a market cap of 11.7B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while TWST trades at $188.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas TWST's P/E ratio is -84.99. In terms of profitability, FBIO's ROE is +1.04%, compared to TWST's ROE of -0.30%. Regarding short-term risk, FBIO is less volatile compared to TWST. This indicates lower risk in terms of short-term price fluctuations for FBIO.Check TWST's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
FBIO vs MDGL Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, MDGL has a market cap of 11.5B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while MDGL trades at $499.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas MDGL's P/E ratio is -39.02. In terms of profitability, FBIO's ROE is +1.04%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, FBIO is more volatile compared to MDGL. This indicates higher risk in terms of short-term price fluctuations for FBIO.Check MDGL's competition here
Bio-Techne Corporation (NASDAQ: TECH)
FBIO vs TECH Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, TECH has a market cap of 11.3B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while TECH trades at $72.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas TECH's P/E ratio is 37.32. In terms of profitability, FBIO's ROE is +1.04%, compared to TECH's ROE of +0.09%. Regarding short-term risk, FBIO is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for FBIO.Check TECH's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
FBIO vs RNAM Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas RNAM's P/E ratio is -17.39. In terms of profitability, FBIO's ROE is +1.04%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, FBIO is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for FBIO.Check RNAM's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
FBIO vs BMRN Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, BMRN has a market cap of 11.1B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while BMRN trades at $57.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas BMRN's P/E ratio is 27.49. In terms of profitability, FBIO's ROE is +1.04%, compared to BMRN's ROE of +0.01%. Regarding short-term risk, FBIO is more volatile compared to BMRN. This indicates higher risk in terms of short-term price fluctuations for FBIO.Check BMRN's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
FBIO vs IBRX Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, IBRX has a market cap of 10.8B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while IBRX trades at $10.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas IBRX's P/E ratio is -10.60. In terms of profitability, FBIO's ROE is +1.04%, compared to IBRX's ROE of +1.35%. Regarding short-term risk, FBIO is less volatile compared to IBRX. This indicates lower risk in terms of short-term price fluctuations for FBIO.Check IBRX's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
FBIO vs RXDX Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas RXDX's P/E ratio is -56.47. In terms of profitability, FBIO's ROE is +1.04%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, FBIO is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for FBIO.Check RXDX's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
FBIO vs KRYS Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, KRYS has a market cap of 9.5B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while KRYS trades at $322.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas KRYS's P/E ratio is 40.39. In terms of profitability, FBIO's ROE is +1.04%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, FBIO is more volatile compared to KRYS. This indicates higher risk in terms of short-term price fluctuations for FBIO.Check KRYS's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
FBIO vs AXSM Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, AXSM has a market cap of 9.2B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while AXSM trades at $177.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas AXSM's P/E ratio is -46.80. In terms of profitability, FBIO's ROE is +1.04%, compared to AXSM's ROE of -2.56%. Regarding short-term risk, FBIO is less volatile compared to AXSM. This indicates lower risk in terms of short-term price fluctuations for FBIO.Check AXSM's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
FBIO vs NUVL Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas NUVL's P/E ratio is -21.79. In terms of profitability, FBIO's ROE is +1.04%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, FBIO is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for FBIO.Check NUVL's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
FBIO vs ARWR Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, ARWR has a market cap of 9B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while ARWR trades at $64.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas ARWR's P/E ratio is -28.53. In terms of profitability, FBIO's ROE is +1.04%, compared to ARWR's ROE of -0.61%. Regarding short-term risk, FBIO is more volatile compared to ARWR. This indicates higher risk in terms of short-term price fluctuations for FBIO.Check ARWR's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
FBIO vs PTGX Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, PTGX has a market cap of 9B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while PTGX trades at $140.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas PTGX's P/E ratio is 135.98. In terms of profitability, FBIO's ROE is +1.04%, compared to PTGX's ROE of +0.12%. Regarding short-term risk, FBIO is more volatile compared to PTGX. This indicates higher risk in terms of short-term price fluctuations for FBIO.Check PTGX's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
FBIO vs CRNX Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, CRNX has a market cap of 9B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while CRNX trades at $84.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas CRNX's P/E ratio is -16.86. In terms of profitability, FBIO's ROE is +1.04%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, FBIO is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for FBIO.Check CRNX's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
FBIO vs KYMR Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, KYMR has a market cap of 8.8B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while KYMR trades at $107.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas KYMR's P/E ratio is -33.56. In terms of profitability, FBIO's ROE is +1.04%, compared to KYMR's ROE of -0.22%. Regarding short-term risk, FBIO is less volatile compared to KYMR. This indicates lower risk in terms of short-term price fluctuations for FBIO.Check KYMR's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
FBIO vs IMGN Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas IMGN's P/E ratio is -111.55. In terms of profitability, FBIO's ROE is +1.04%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, FBIO is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for FBIO.Check IMGN's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
FBIO vs BPMC Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas BPMC's P/E ratio is -51.58. In terms of profitability, FBIO's ROE is +1.04%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, FBIO is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for FBIO.Check BPMC's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
FBIO vs APGE Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, APGE has a market cap of 8.4B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while APGE trades at $135.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas APGE's P/E ratio is -31.19. In terms of profitability, FBIO's ROE is +1.04%, compared to APGE's ROE of -0.30%. Regarding short-term risk, FBIO is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for FBIO.Check APGE's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
FBIO vs TGTX Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, TGTX has a market cap of 8.3B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while TGTX trades at $54.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas TGTX's P/E ratio is 19.67. In terms of profitability, FBIO's ROE is +1.04%, compared to TGTX's ROE of +0.72%. Regarding short-term risk, FBIO is more volatile compared to TGTX. This indicates higher risk in terms of short-term price fluctuations for FBIO.Check TGTX's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
FBIO vs PRAX Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, PRAX has a market cap of 8.2B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while PRAX trades at $295.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas PRAX's P/E ratio is -22.85. In terms of profitability, FBIO's ROE is +1.04%, compared to PRAX's ROE of -0.34%. Regarding short-term risk, FBIO is less volatile compared to PRAX. This indicates lower risk in terms of short-term price fluctuations for FBIO.Check PRAX's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
FBIO vs CERE Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas CERE's P/E ratio is -16.47. In terms of profitability, FBIO's ROE is +1.04%, compared to CERE's ROE of -0.72%. Regarding short-term risk, FBIO is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for FBIO.Check CERE's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
FBIO vs CYTK Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, CYTK has a market cap of 8.2B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while CYTK trades at $65.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas CYTK's P/E ratio is -9.09. In terms of profitability, FBIO's ROE is +1.04%, compared to CYTK's ROE of +1.64%. Regarding short-term risk, FBIO is more volatile compared to CYTK. This indicates higher risk in terms of short-term price fluctuations for FBIO.Check CYTK's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
FBIO vs PCVX Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, PCVX has a market cap of 8.2B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while PCVX trades at $56.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas PCVX's P/E ratio is -7.40. In terms of profitability, FBIO's ROE is +1.04%, compared to PCVX's ROE of -0.38%. Regarding short-term risk, FBIO is more volatile compared to PCVX. This indicates higher risk in terms of short-term price fluctuations for FBIO.Check PCVX's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
FBIO vs SYRE Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, SYRE has a market cap of 8.1B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while SYRE trades at $93.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas SYRE's P/E ratio is -47.79. In terms of profitability, FBIO's ROE is +1.04%, compared to SYRE's ROE of -0.24%. Regarding short-term risk, FBIO is less volatile compared to SYRE. This indicates lower risk in terms of short-term price fluctuations for FBIO.Check SYRE's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
FBIO vs CAI Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, CAI has a market cap of 8B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while CAI trades at $28.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas CAI's P/E ratio is 79.52. In terms of profitability, FBIO's ROE is +1.04%, compared to CAI's ROE of +0.19%. Regarding short-term risk, FBIO is more volatile compared to CAI. This indicates higher risk in terms of short-term price fluctuations for FBIO.Check CAI's competition here
Metsera, Inc. (NASDAQ: MTSR)
FBIO vs MTSR Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas MTSR's P/E ratio is -23.58. In terms of profitability, FBIO's ROE is +1.04%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, FBIO is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for FBIO.Check MTSR's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
FBIO vs IONS Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, IONS has a market cap of 7.2B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while IONS trades at $43.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas IONS's P/E ratio is -13.31. In terms of profitability, FBIO's ROE is +1.04%, compared to IONS's ROE of -1.11%. Regarding short-term risk, FBIO is more volatile compared to IONS. This indicates higher risk in terms of short-term price fluctuations for FBIO.Check IONS's competition here
Immunovant, Inc. (NASDAQ: IMVT)
FBIO vs IMVT Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, IMVT has a market cap of 6.9B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while IMVT trades at $33.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas IMVT's P/E ratio is -11.92. In terms of profitability, FBIO's ROE is +1.04%, compared to IMVT's ROE of -0.70%. Regarding short-term risk, FBIO is more volatile compared to IMVT. This indicates higher risk in terms of short-term price fluctuations for FBIO.Check IMVT's competition here
Merus N.V. (NASDAQ: MRUS)
FBIO vs MRUS Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas MRUS's P/E ratio is -17.05. In terms of profitability, FBIO's ROE is +1.04%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, FBIO is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for FBIO.Check MRUS's competition here
Abivax S.A. (NASDAQ: ABVX)
FBIO vs ABVX Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, ABVX has a market cap of 6.8B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while ABVX trades at $92.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas ABVX's P/E ratio is -15.22. In terms of profitability, FBIO's ROE is +1.04%, compared to ABVX's ROE of -0.99%. Regarding short-term risk, FBIO is more volatile compared to ABVX. This indicates higher risk in terms of short-term price fluctuations for FBIO.Check ABVX's competition here
Arcellx, Inc. (NASDAQ: ACLX)
FBIO vs ACLX Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas ACLX's P/E ratio is -28.27. In terms of profitability, FBIO's ROE is +1.04%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, FBIO is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for FBIO.Check ACLX's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
FBIO vs RETA Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas RETA's P/E ratio is -66.29. In terms of profitability, FBIO's ROE is +1.04%, compared to RETA's ROE of +0.47%. Regarding short-term risk, FBIO is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for FBIO.Check RETA's competition here
Belite Bio, Inc (NASDAQ: BLTE)
FBIO vs BLTE Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, BLTE has a market cap of 6.4B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while BLTE trades at $160.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas BLTE's P/E ratio is -85.33. In terms of profitability, FBIO's ROE is +1.04%, compared to BLTE's ROE of -0.16%. Regarding short-term risk, FBIO is more volatile compared to BLTE. This indicates higher risk in terms of short-term price fluctuations for FBIO.Check BLTE's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
FBIO vs RYTM Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, RYTM has a market cap of 6.4B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while RYTM trades at $92.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas RYTM's P/E ratio is -29.85. In terms of profitability, FBIO's ROE is +1.04%, compared to RYTM's ROE of -0.80%. Regarding short-term risk, FBIO is more volatile compared to RYTM. This indicates higher risk in terms of short-term price fluctuations for FBIO.Check RYTM's competition here
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA)
FBIO vs IOVA Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, IOVA has a market cap of 6.3B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while IOVA trades at $14.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas IOVA's P/E ratio is -19.47. In terms of profitability, FBIO's ROE is +1.04%, compared to IOVA's ROE of -0.41%. Regarding short-term risk, FBIO is less volatile compared to IOVA. This indicates lower risk in terms of short-term price fluctuations for FBIO.Check IOVA's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
FBIO vs CNTA Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas CNTA's P/E ratio is -22.63. In terms of profitability, FBIO's ROE is +1.04%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, FBIO is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for FBIO.Check CNTA's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
FBIO vs LGND Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, LGND has a market cap of 6.1B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while LGND trades at $302.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas LGND's P/E ratio is 33.26. In terms of profitability, FBIO's ROE is +1.04%, compared to LGND's ROE of +0.20%. Regarding short-term risk, FBIO is more volatile compared to LGND. This indicates higher risk in terms of short-term price fluctuations for FBIO.Check LGND's competition here
CG Oncology Inc. (NASDAQ: CGON)
FBIO vs CGON Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, CGON has a market cap of 5.9B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while CGON trades at $67.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas CGON's P/E ratio is -25.05. In terms of profitability, FBIO's ROE is +1.04%, compared to CGON's ROE of -0.25%. Regarding short-term risk, FBIO is less volatile compared to CGON. This indicates lower risk in terms of short-term price fluctuations for FBIO.Check CGON's competition here
Kodiak Sciences Inc. (NASDAQ: KOD)
FBIO vs KOD Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, KOD has a market cap of 5.9B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while KOD trades at $94.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas KOD's P/E ratio is -22.65. In terms of profitability, FBIO's ROE is +1.04%, compared to KOD's ROE of -2.73%. Regarding short-term risk, FBIO is less volatile compared to KOD. This indicates lower risk in terms of short-term price fluctuations for FBIO.Check KOD's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
FBIO vs CDTX Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas CDTX's P/E ratio is -19.77. In terms of profitability, FBIO's ROE is +1.04%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, FBIO is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for FBIO.Check CDTX's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
FBIO vs SRRK Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, SRRK has a market cap of 5.6B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while SRRK trades at $46.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas SRRK's P/E ratio is -13.57. In terms of profitability, FBIO's ROE is +1.04%, compared to SRRK's ROE of -1.60%. Regarding short-term risk, FBIO is more volatile compared to SRRK. This indicates higher risk in terms of short-term price fluctuations for FBIO.Check SRRK's competition here
Abcam plc (NASDAQ: ABCM)
FBIO vs ABCM Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, FBIO's ROE is +1.04%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, FBIO is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for FBIO.Check ABCM's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
FBIO vs ISEE Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas ISEE's P/E ratio is -22.44. In terms of profitability, FBIO's ROE is +1.04%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, FBIO is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for FBIO.Check ISEE's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
FBIO vs CRSP Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, CRSP has a market cap of 5.3B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while CRSP trades at $55.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas CRSP's P/E ratio is -11.64. In terms of profitability, FBIO's ROE is +1.04%, compared to CRSP's ROE of -0.24%. Regarding short-term risk, FBIO is less volatile compared to CRSP. This indicates lower risk in terms of short-term price fluctuations for FBIO.Check CRSP's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
FBIO vs COGT Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, COGT has a market cap of 5.3B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while COGT trades at $31.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas COGT's P/E ratio is -14.70. In terms of profitability, FBIO's ROE is +1.04%, compared to COGT's ROE of -0.73%. Regarding short-term risk, FBIO is less volatile compared to COGT. This indicates lower risk in terms of short-term price fluctuations for FBIO.Check COGT's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
FBIO vs PTCT Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, PTCT has a market cap of 5.3B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while PTCT trades at $63.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas PTCT's P/E ratio is -27.24. In terms of profitability, FBIO's ROE is +1.04%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, FBIO is more volatile compared to PTCT. This indicates higher risk in terms of short-term price fluctuations for FBIO.Check PTCT's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
FBIO vs TVTX Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, TVTX has a market cap of 5.3B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while TVTX trades at $56.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas TVTX's P/E ratio is -126.51. In terms of profitability, FBIO's ROE is +1.04%, compared to TVTX's ROE of -0.56%. Regarding short-term risk, FBIO is more volatile compared to TVTX. This indicates higher risk in terms of short-term price fluctuations for FBIO.Check TVTX's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
FBIO vs APLS Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas APLS's P/E ratio is 38.35. In terms of profitability, FBIO's ROE is +1.04%, compared to APLS's ROE of +0.40%. Regarding short-term risk, FBIO is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for FBIO.Check APLS's competition here
Erasca, Inc. (NASDAQ: ERAS)
FBIO vs ERAS Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, ERAS has a market cap of 5.1B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while ERAS trades at $14.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas ERAS's P/E ratio is -15.85. In terms of profitability, FBIO's ROE is +1.04%, compared to ERAS's ROE of -0.80%. Regarding short-term risk, FBIO is less volatile compared to ERAS. This indicates lower risk in terms of short-term price fluctuations for FBIO.Check ERAS's competition here
Oruka Therapeutics, Inc. (NASDAQ: ORKA)
FBIO vs ORKA Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, ORKA has a market cap of 5.1B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while ORKA trades at $84.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas ORKA's P/E ratio is -43.57. In terms of profitability, FBIO's ROE is +1.04%, compared to ORKA's ROE of -0.21%. Regarding short-term risk, FBIO is more volatile compared to ORKA. This indicates higher risk in terms of short-term price fluctuations for FBIO.Check ORKA's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
FBIO vs MIRM Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, MIRM has a market cap of 5.1B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while MIRM trades at $82.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas MIRM's P/E ratio is -5.70. In terms of profitability, FBIO's ROE is +1.04%, compared to MIRM's ROE of -4.10%. Regarding short-term risk, FBIO is less volatile compared to MIRM. This indicates lower risk in terms of short-term price fluctuations for FBIO.Check MIRM's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
FBIO vs DFTX Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, DFTX has a market cap of 5B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while DFTX trades at $37.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas DFTX's P/E ratio is N/A. In terms of profitability, FBIO's ROE is +1.04%, compared to DFTX's ROE of -0.85%. Regarding short-term risk, FBIO is more volatile compared to DFTX. This indicates higher risk in terms of short-term price fluctuations for FBIO.Check DFTX's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
FBIO vs DNTH Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, DNTH has a market cap of 4.9B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while DNTH trades at $88.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas DNTH's P/E ratio is -21.26. In terms of profitability, FBIO's ROE is +1.04%, compared to DNTH's ROE of -0.04%. Regarding short-term risk, FBIO is less volatile compared to DNTH. This indicates lower risk in terms of short-term price fluctuations for FBIO.Check DNTH's competition here
Veradermics, Incorporated (NYSE: MANE)
FBIO vs MANE Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, MANE has a market cap of 4.9B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while MANE trades at $116.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas MANE's P/E ratio is -37.17. In terms of profitability, FBIO's ROE is +1.04%, compared to MANE's ROE of -0.38%. Regarding short-term risk, FBIO is less volatile compared to MANE. This indicates lower risk in terms of short-term price fluctuations for FBIO.Check MANE's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
FBIO vs TERN Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas TERN's P/E ratio is -51.41. In terms of profitability, FBIO's ROE is +1.04%, compared to TERN's ROE of -0.20%. Regarding short-term risk, FBIO is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for FBIO.Check TERN's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
FBIO vs FOLD Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas FOLD's P/E ratio is -161.00. In terms of profitability, FBIO's ROE is +1.04%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, FBIO is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for FBIO.Check FOLD's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
FBIO vs ADPT Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, ADPT has a market cap of 4.5B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while ADPT trades at $28.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas ADPT's P/E ratio is -69.15. In terms of profitability, FBIO's ROE is +1.04%, compared to ADPT's ROE of -0.33%. Regarding short-term risk, FBIO is more volatile compared to ADPT. This indicates higher risk in terms of short-term price fluctuations for FBIO.Check ADPT's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
FBIO vs AKRO Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas AKRO's P/E ratio is -14.57. In terms of profitability, FBIO's ROE is +1.04%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, FBIO is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for FBIO.Check AKRO's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
FBIO vs ALPN Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas ALPN's P/E ratio is -101.52. In terms of profitability, FBIO's ROE is +1.04%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, FBIO is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for FBIO.Check ALPN's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
FBIO vs EWTX Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, EWTX has a market cap of 4.5B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while EWTX trades at $41.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas EWTX's P/E ratio is -22.38. In terms of profitability, FBIO's ROE is +1.04%, compared to EWTX's ROE of -0.39%. Regarding short-term risk, FBIO is more volatile compared to EWTX. This indicates higher risk in terms of short-term price fluctuations for FBIO.Check EWTX's competition here
Opthea Limited (NASDAQ: OPT)
FBIO vs OPT Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas OPT's P/E ratio is -1.52. In terms of profitability, FBIO's ROE is +1.04%, compared to OPT's ROE of +1.18%. Regarding short-term risk, FBIO is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for FBIO.Check OPT's competition here
PureTech Health plc (NASDAQ: PRTC)
FBIO vs PRTC Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while PRTC trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas PRTC's P/E ratio is -3.78. In terms of profitability, FBIO's ROE is +1.04%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, FBIO is more volatile compared to PRTC. This indicates higher risk in terms of short-term price fluctuations for FBIO.Check PRTC's competition here
AbCellera Biologics Inc. (NASDAQ: ABCL)
FBIO vs ABCL Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, ABCL has a market cap of 4.2B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while ABCL trades at $13.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas ABCL's P/E ratio is -25.44. In terms of profitability, FBIO's ROE is +1.04%, compared to ABCL's ROE of -0.17%. Regarding short-term risk, FBIO is less volatile compared to ABCL. This indicates lower risk in terms of short-term price fluctuations for FBIO.Check ABCL's competition here
Relay Therapeutics, Inc. (NASDAQ: RLAY)
FBIO vs RLAY Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, RLAY has a market cap of 4.2B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while RLAY trades at $18.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas RLAY's P/E ratio is -12.08. In terms of profitability, FBIO's ROE is +1.04%, compared to RLAY's ROE of -0.42%. Regarding short-term risk, FBIO is more volatile compared to RLAY. This indicates higher risk in terms of short-term price fluctuations for FBIO.Check RLAY's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
FBIO vs MRTX Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas MRTX's P/E ratio is -4.82. In terms of profitability, FBIO's ROE is +1.04%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, FBIO is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for FBIO.Check MRTX's competition here
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
FBIO vs CPRX Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas CPRX's P/E ratio is 17.49. In terms of profitability, FBIO's ROE is +1.04%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, FBIO is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for FBIO.Check CPRX's competition here
Tango Therapeutics, Inc. (NASDAQ: TNGX)
FBIO vs TNGX Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, TNGX has a market cap of 3.8B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while TNGX trades at $23.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas TNGX's P/E ratio is -28.00. In terms of profitability, FBIO's ROE is +1.04%, compared to TNGX's ROE of -0.26%. Regarding short-term risk, FBIO is less volatile compared to TNGX. This indicates lower risk in terms of short-term price fluctuations for FBIO.Check TNGX's competition here
RayzeBio, Inc. Common Stock (NASDAQ: RYZB)
FBIO vs RYZB Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas RYZB's P/E ratio is -57.86. In terms of profitability, FBIO's ROE is +1.04%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, FBIO is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for FBIO.Check RYZB's competition here
CymaBay Therapeutics, Inc. (NASDAQ: CBAY)
FBIO vs CBAY Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas CBAY's P/E ratio is -32.81. In terms of profitability, FBIO's ROE is +1.04%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, FBIO is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for FBIO.Check CBAY's competition here
Xenon Pharmaceuticals Inc. (NASDAQ: XENE)
FBIO vs XENE Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, XENE has a market cap of 3.7B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while XENE trades at $38.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas XENE's P/E ratio is -8.09. In terms of profitability, FBIO's ROE is +1.04%, compared to XENE's ROE of -0.44%. Regarding short-term risk, FBIO is less volatile compared to XENE. This indicates lower risk in terms of short-term price fluctuations for FBIO.Check XENE's competition here
Telix Pharmaceuticals Limited (NASDAQ: TLX)
FBIO vs TLX Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, TLX has a market cap of 3.6B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while TLX trades at $10.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas TLX's P/E ratio is 110.13. In terms of profitability, FBIO's ROE is +1.04%, compared to TLX's ROE of +0.07%. Regarding short-term risk, FBIO is more volatile compared to TLX. This indicates higher risk in terms of short-term price fluctuations for FBIO.Check TLX's competition here
IDEAYA Biosciences, Inc. (NASDAQ: IDYA)
FBIO vs IDYA Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, IDYA has a market cap of 3.6B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while IDYA trades at $37.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas IDYA's P/E ratio is -19.26. In terms of profitability, FBIO's ROE is +1.04%, compared to IDYA's ROE of -0.16%. Regarding short-term risk, FBIO is less volatile compared to IDYA. This indicates lower risk in terms of short-term price fluctuations for FBIO.Check IDYA's competition here
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX)
FBIO vs SWTX Comparison October 2026
Fortress Biotech, Inc. (NASDAQ: FBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, FBIO stands at 67.4M. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, FBIO is priced at $2.03 on the NASDAQ, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
FBIO currently has a P/E ratio of 0.77, whereas SWTX's P/E ratio is -13.78. In terms of profitability, FBIO's ROE is +1.04%, compared to SWTX's ROE of -0.47%. Regarding short-term risk, FBIO is more volatile compared to SWTX. This indicates higher risk in terms of short-term price fluctuations for FBIO.Check SWTX's competition here